Tier 3 — preclinical

Quercetin Protects Intestinal Barrier Integrity in Inflammation and Oxidative Stress

Olugbenga Balogun, Hye Won Kang
Nutrients 2026 18(13):2169

Bibliography

PubMed
PMID 42451170
PubMed Central
PMC13363914
DOI
10.3390/nu18132169
Funding
Funding was not confirmed from the indexed record; consult the original publication.
Competing interests
The authors declare no conflicts of interest.

Study snapshot

DesignDietary intervention and intestinal mechanism study in mice
ModelAnimal or laboratory evidence
SampleHigh-fat and low-fat diet mouse groups; exact group sizes not stated in the indexed abstract
InterventionDiet with or without 1% quercetin in experimental mice
DurationExperimental feeding schedule; exact duration requires full methods
EndpointsModel-specific outcomes; see methods and findings

What the study showed, in plain terms

Published in 2026, this source examined gut and intestinal health. Design: Dietary intervention and intestinal mechanism study in mice. Sample/model: High-fat and low-fat diet mouse groups; exact group sizes not stated in the indexed abstract. The exposure or intervention was Diet with or without 1% quercetin in experimental mice. Follow-up or treatment period: Experimental feeding schedule; exact duration requires full methods.

Quercetin improved selected intestinal-barrier, inflammatory and signalling measures in high-fat-fed mice.

Animal dietary exposure and mechanistic endpoints. Human gut-repair efficacy, an oral clinical dose and treatment of IBS or IBD were not established.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Gut Health: Microbiome and Barrier Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Quercetin improved selected intestinal-barrier, inflammatory and signalling measures in high-fat-fed mice.
  • The recorded outcome domains were Model-specific outcomes; see methods and findings.
  • The result applies to the tested exposure: Diet with or without 1% quercetin in experimental mice; Experimental feeding schedule; exact duration requires full methods.

What this study can and cannot tell us

  • Animal dietary exposure and mechanistic endpoints. Human gut-repair efficacy, an oral clinical dose and treatment of IBS or IBD were not established.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this record. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 3
Preclinical evidence for quercetin against inflammatory bowel disease: a meta-analysis and systematic review
Shuangyuan Hu et al. · Inflammopharmacology · 2022
Tier 4
Higher Dietary Quercetin Intake Is Associated with Lower Risk of Adverse Outcomes among Individuals with Inflammatory Bowel Disease in a Prospective Cohort Study
Tianyu Wang et al. · The Journal of nutrition · 2024

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology